SMi is launching its inaugural Immunogenicity Conference, taking place in London on the 14th and 15th July.

Medical & Health Care, Pharmaceuticals/Drug Discovery

Submit new post
Thank you for posting.
Share it:

SMi are launching an Immunogenicity Conference, a two day event designed to become the leaders’ favourite with an ever growing demand for biologic therapeutics in the Pharmaceutical Industry.

We ask the questions;

What stimulates an immune response? How does the system cope with immunogenic compounds? And how do you screen for potential problems?

The Conference will address all these concerns and enable Clinical Immunologists, Physicians and Specialists within the field of Immunogenicity to discuss the major challenges currently being faced within the pharmaceutical industry.

The focus is on pre-clinical analysis and assessing treatments for clinical development. It will endeavour to look at the assessment of early risks in immunogenicity and the evaluation of in silico tools for determining immunogenicity. With an insight into the safety, development and validation of Monoclonal Antibodies.

Further to this, the main interest emerging is the tissue quality and preservation in which the therapeutics are being put into. The conference will evaluate what happens to them in vivo along with a regulatory perspective.

A key session on Immunomodulation will enable delegates to get an understanding of how to evaluate the best read outs and best elements of immune response. Immunogenicity is a hurdle one looks to overcome and with the likes of aggregation being a factor when handling proteins, a key session on immunological tolerance will look to address this.

From a clinical perspective, the conference will assess consideration and design of biologic therapeutics, clinical Implications and review what the clinical outcomes are from using these immune modulatory approaches.

The conference will also look at, how to benefit the patient by assessing efficacy and toxicological concerns alongside the management of immunogenic responses. With regulators supposing that animal studies are not good predictors – how can predictability be shown with pre-clinical in-vitro tools?

Benefits of Attending

• Gain insight into the assessment of early risks in immunogenicity and major hurdles in clinical development

• Assess considerations and design of biologic therapeutics and the clinical Implications

• Hear the latest on in silico tools being utilised for the determination of immunogenicity

• Enhance immunomodulation understanding on how to evaluate the best read outs for immune response

• Hear how predictability can be shown with pre-clinical in-vitro tools from a regulatory perspective

CEO, CSO, Vice President, Director, Biology Research, Associate Scientific Director, Head of R&D, Research Associate, Research Scientist, Senior Scientist, Clinical Immunologists in the field of:

• Rheumatology

• Immunology

• Auto Immune Disease

• Oncology

• Pathology